|
|
|
|
|
|
|
|
abstract
Highlights
- •
- Optimal management of women with borderline ovarian tumour (BOT) is controversial
- •
- Relapse and survival was evaluated combining data from national registries
- •
- A total of 3.7% and 0.6% of 1143 women experienced relapse or died from their BOT.
- •
- Long-term follow-up is not necessary in stage IA BOT and no residual disease or microinvasion
Abstract
Objective
The
aim of the study was to evaluate the rate of relapse as well as
disease-free, overall, and disease-specific survival in women with
borderline ovarian tumour (BOT). Furthermore, the study aims to identify
the clinical parameters correlated to relapse.
Methods
National
clinical data of women diagnosed with BOT from January 2005 to January
2013 constituted the basis for our study population. The prognostic
influence of clinical variables was evaluated using univariate and
multivariate analyses.
Results
A
total of 1143 women were eligible for analysis, with 87.9% in FIGO
stage I and 12.1% in FIGO stages II–IV. Relapse of BOT was detected in
3.7%, hereof 40.5% with malignant transformation. The five-year
disease-free survival was 97.6% in FIGO stage I and 87.3% in FIGO stages
II–IV. Younger age, laparoscopic surgical approach, fertility sparing
surgery, FIGO stages II–IV, bilateral tumour presence, serous histology,
implants and microinvasion of the tumour were significantly associated
with relapse in univariate analyses. The overall five-year survival rate
was 92.2% in FIGO stage I and 89.0% in FIGO stages II–IV. Out of 77
deaths in total, only seven women died from BOT.
Conclusions
A
general favourable prognosis in women with BOT was confirmed in our
study. Our findings indicate that systematic, long-term follow-up does
not seem necessary in women treated for FIGO stage IA BOT with no
residual disease or microinvasion.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.